A MULTICENTRIC STUDY ON BREAST CANCER IN ULTRA YOUNG WOMEN: II – HISTOPATHOLOGIC AND MOLECULAR DATA

Adriana Akemi Yoshimura1, André Mattar2, Bruna S. Mota3, Carlos Elias Fristachi4, Eduardo Carvalho Pessoa5, Felipe Eduardo Andrade6, Giuliano Tosello7, Mário De Luca Vespoli8, Idam de Oliveira Junior9, João Bosco Ramos Borges9, José Roberto Filassi10, Luiz Henrique Gebrim11, Marina Filie Haddad Piccinilli10, René Aloisio Costa Vieira12, Vicente Tarconico Junior13, Alfredo Carlos Simões Dornellas de Barros1

1Hospital da Beneficência Portuguesa – São Paulo (SP), Brazil.
2Hospital Pérola Byington – São Paulo (SP), Brazil.
3Instituto do Câncer do Estado de São Paulo – São Paulo (SP), Brazil.
4Instituto Arnaldo Vieira de Carvalho – São Paulo (SP), Brazil.
5Hospital das Clínicas de Botucatu – Botucatu (SP), Brazil.
6Hospital Sírio Libanês – São Paulo (SP), Brazil.
7Hospital Regional de Presidente Prudente – Presidente Prudente (SP), Brazil.
8Hospital do Amor – Barretos (SP), Brazil.
9Faculdade de Medicina de Jundiaí – Jundiaí (SP), Brazil.
10Faculdade de Ciências Médicas de Santos – Santos (SP), Brazil.

Introduction: Ultra young women (UYW) is defined as women aged up to 30 years. UYW with BC share some unfavorable biological tumor characteristics as larger size at diagnosis, higher loco-regional recurrence rate and lower survival, and have been merited specialized care. Objectives: We aimed to determine histopathological and molecular characteristics of BC in UYW. Methods: We carried out a multicentric, observational, retrospective study of consecutive UYW patients with BC. Only patients with infiltrating BC were included. Nine Mastology Centers located in the State of São Paulo took part in the research. The follow data were recorded: pathological tumor histology, number of positive lymph nodes multicentricity/multifocality, presence or absence of peritumoral vascular invasion (PVI), histologic grade (HG), pT category, estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki67. We classified the neoplasias into five molecular subtypes by immunohistochemistry, based on modified recommendations of St. Gallen Consensus (2013): Luminal A-like, Luminal B-like HER2-, Luminal B-like HER2+, HER2 overexpressed (HER2+) non luminal and Triple-Negative. The frequency of the analyzed parameters were calculated. The research protocol was approved by the Ethics Committee of all Collaborative Centers. Individual informed consent was waived. Results: Invasive carcinoma of no special type (NST) was observed in 243 patients (88%), and infiltrative lobular tumor was extremely rare, being found in 1.1%. The tumor size in surgical specimens was above 20 mm in 54% (in 10% there was no more evidence of tumor after neoadjuvant treatment). We found 52.6% of patients without invasion in lymph nodes (LN) whereas in 22.2% there was more than four LNs involved. Multifocality was seen in 12.4%. HG was 2 or 3 in 98.3%. In 67.5% the tumors expressed ER, 59.4% gR, and 25.1% were HER2+. In 61.5% Ki67 was higher than 20%. Tumor molecular subtypes were classified in 16.6% Luminal A-like, 35.9% Luminal B-like HER2-, 15.1% Luminal B-like HER2+, 9.3% HER2+ non-luminal and in 22.9% Basal-like. Conclusions: Our data from UYW with BC revealed unfavorable characteristics, with frequent adverse pathological and molecular prognostic factors.